CAMMS · CAMMS3240057
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
Estudio aleatorizado ciego para el evaluador y de dosis ciega de fase III que compara dos ciclos anuales intravenosos de dosis bajas y alta de alemtuzumab con interferón beta-1a (Redif)subcutáneo tres vece a la semana en pacientes con esclerosis múltiple EUDRACT: 2007-001162-32
Historical record notice: The original Spanish study title is incomplete. It is shown as recorded, without guessing the missing information.
Sponsor: GENZYME
Phase: III
Area: Neuroimmunology